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Abstract
Smoking is a significant risk factor for pancreatic cancer, but the molecular mechanisms by which tobacco smoke
components promote the growth and progression of these cancers are not fully understood. While nicotine, the
addictive component of tobacco smoke, is not a carcinogen, it has been shown to promote the growth of non–
small cell lung and pancreatic cancers in a receptor-dependent fashion. Here, we show that stimulation of pancre-
atic cancer cells with nicotine concentrations that are within the range of human exposure results in activation of
Src kinase, which facilitated the induction of the inhibitor of differentiation-1 (Id1) transcription factor. Depletion of
Id1 prevented nicotine-mediated induction of proliferation and invasion of pancreatic cancer cells, indicating that it
is a major mediator of nicotine function. Nicotine could promote the growth and metastasis of pancreatic cancers
orthotopically implanted into SCID mice; in addition, cells stably expressing a short hairpin RNA for Id1 did not grow
or metastasize in response to nicotine. Nicotine could also confer resistance to apoptosis induced by gemcitabine
in pancreatic cancer cells in vitro and depletion of Src or Id1 rendered the cells sensitive to gemcitabine. Further,
nicotine could effectively inhibit the chemotherapeutic effects of gemcitabine on pancreatic tumors xenografted
into mice. Clinical analyses of resected pancreatic cancer specimens demonstrated a statistically significant corre-
lation between Id1 expression and phospho-Src, tumor grade/differentiation, and worsening overall patient survival.
These results demonstrate that exposure to tobacco smoke components might promote pancreatic cancer pro-
gression, metastasis, and chemoresistance and highlight the role of Id1 in these processes.
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Introduction
Pancreatic adenocarcinoma is the fourth leading cause of cancer-
related deaths in the United States [1]. In 2011, it is estimated that
44,030 people will be diagnosed with pancreatic adenocarcinoma
and 37,660 people will die of this disease [2]. Less than 20% of
patients are allowed a surgical option that is presently the only poten-
tial for cure. Regardless, the overall 5-year survival remains less than
5%, with gemcitabine-based chemotherapeutic strategies partly due
to the development of chemoresistance [1]. The molecular mecha-
nisms that underlie gemcitabine resistance have not been fully defined
[3,4]. Recent evidence suggests that deregulation of certain signaling
molecules not only play a critical role in pancreatic tumor progression
but can also facilitate chemoresistance [5].
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Presently, the only established risk factor for pancreatic cancer is
tobacco use [6,7]. Although exposure to cigarette smoke components such
as polycyclic aromatic hydrocarbons and tobacco-specific N -nitrosamines
have resulted in epigenetic events in human pancreatic ductal epithelial
cells [8], the mechanism of how tobacco smoke components affects
tumor growth and other malignant properties is not clearly understood.
Evidence from our laboratory suggests that nicotine, the addictive com-
ponent of tobacco, acts a tumor promoter in non–small cell lung cancer
(NSCLC) cell lines potentially through Src-dependent phosphoinositide
3-kinase (PI3K)/Akt pathways [9]. Nicotine could inhibit apoptosis in-
duced by chemotherapeutic drugs [9,10] in NSCLC cells, through the
up-regulation of X-linked inhibitor of apoptosis protein (XIAP) and sur-
vivin. Recent evidence supports the role of nicotine on nicotinic acetyl-
choline receptors (nAChRs), and β-adrenergic receptors stimulate the
growth and migration of pancreatic cancer cells [11,12]. It has been sug-
gested that activation of these receptors through an autocrine catecholo-
mine loop contribute to activation of Src, Erk mitogen-activated protein
kinase (MAPK), and Akt signaling cascades [13]. Additionally, nicotine
and cigarette smoke have been recently implicated in promotion of a me-
tastatic phenotype through the activation of the α7 subunit of nAChR
through the JAK2/STAT3downstream signaling cascade [14]. Additionally,
c-Src has been implicated in pancreatic tumor angiogenesis and metastasis
[15,16] and its activation and overexpression contributes to a chemo-
resistant phenotype in pancreatic cancer preclinical models [17–19].
Although Src seems to play a pivotal role in these processes, the mecha-
nisms accelerating Src signaling and the key Src-dependent downstream
signaling pathways contributing to these aggressive and chemoresistant
phenotype in pancreatic cancer are not clearly understood.
Studies on NSCLC cell lines have identified nicotine as a mitogen
that induces proliferation by activating Src, with a concomitant increase
in inhibitor of differentiation-1 (Id1) transcription factor [20]. Id1 is a
helix-loop-helix (HLH) protein that plays a role in cell growth, senes-
cence, and differentiation [21]. Its ability to form heterodimers with
members of the basic HLH family of transcription factors leads to
the inhibition of DNA binding and transcriptional repression of certain
tumor suppressor proteins, leading to an oncogenic phenotype [22]. In
preclinical models of pancreatic cancer, double knockdown of Id1/Id3
resulted in decreased metastatic potential [23]. Additionally, over-
expression of Id1 correlates with tumor angiogenesis in resected human
pancreatic cancer specimens [23,24].
While Id1 overexpression has been implicated in chemoresistance in
certain specific systems [25,26], the role of Id1 in pancreatic tumor
chemoresistance and the mechanisms that augment its expression are
currently unknown. Studies presented here show that nicotine induces
Id1 expression in pancreatic adenocarcinoma cells. Inhibition of Id1
prevented the nicotine-mediated proliferation of pancreatic cancer cells
and enhanced their sensitivity to gemcitabine. Further, elimination of
Id1 from cells greatly impaired their ability to form tumors in immuno-
compromised mice and inhibited metastasis. Analysis of human pan-
creatic cancer tissue microarrays (TMAs) showed a direct correlation
between tumor grade, Src phosphorylation, and Id1 levels, suggesting
that enhanced Id1 expression might have contributed to the genesis as
well as growth of these tumors.
Materials and Methods
Cell Lines and Reagents
Human pancreatic cancer cells of ductal origin, PANC-1 and Mia-
PaCa-2, were obtained from ATCC (Rockville, MD) and cultured as
described [27]. The cell line CD18/HPAF was originally derived as
previously described [28]. The L3.6pl metastatic variant pancreatic
cancer cell line was derived from repeated cycle of injecting COLO
357 cells into the pancreas of nude mice, selecting for liver metastases
[15,29]. Gemcitabine (Eli Lilly, Indianapolis, IN) was suspended in
Dulbecco’s phosphate-buffered saline (PBS). Nicotine stimulation was
performed on cells that were rendered quiescent by serum starvation
for 48 hours with 1 μM nicotine (Sigma Chemical Company, St Louis,
MO). Src family kinase inhibitor dasatinib (BMS-354825) was obtained
from Bristol-Myers Squibb (Princeton, NJ).
Selection of L3.6pl GemRes Gemcitabine-resistant
Pancreatic Cancer Cells
Selection of L3.6plGemRes gemcitabine-resistant pancreatic cancer
cells was performed as previously described [17,18]. Briefly, L3.6pl
gemcitabine-sensitive cells were exposed to 5 μM gemcitabine and
steadily increased by 5-μM increments every 2 days to maximal concen-
tration of 30 μM, approximately 12-fold greater than the half-maximal
inhibitory concentration (IC50). Single colonies of gemcitabine-resistant
clones were expanded for further analysis.
Antibodies, Immunoprecipitation, and Western Blot Analysis
Lysates were prepared from cells and tumor tissues, and immuno-
precipitation and Western blots were conducted as previously de-
scribed [30]. Monoclonal Id1 antibodies from BioCheck (Foster
City, CA), monoclonal antibodies to c-Src (Upstate Biotechnology,
Lake Placid, NY), p44/42 Erk MAPK and Akt (5G3) (Cell Signaling
Technology, Beverly, MA), polyclonal α7 nAChR (Abcam, Cambridge,
MA), phospho-Src (pSrc), phospho-AktS473, phospho-p44/42 ErkT202/Y204,
β-actin monoclonal antibody (Sigma, St Louis, MO), and PARP (Cell
Signaling Technology) antibodies were used in Western blot analysis.
Generation of Stable Cell Lines
L3.6pl cells were transfected with pCDNA3.1-luciferase expression
construct using HD Fugene transfection reagent (Roche, Indianapolis,
IN). Stable cells were selected using G418 (200 mg/ml). Individual
clones were maintained in G418 selection media and the expression
of luciferase gene was determined by treatment with luciferin (Caliper
Life Sciences, Alameda, CA) and imaging on IVIS200.
For generation of Id1 null cells, luciferase expressing L3.6pl pan-
creatic cancer cells were stably transfected with short hairpin RNA
(shRNA) constructs that specifically target Id1 (Open Biosystems,
Huntsville, AL). A control cell line was generated by stably transfect-
ing an shRNA that does not target any recognized genes. Luciferase
expressing L3.6pl-Id1-shRNA and L3.6pl-control-shRNA cell lines,
referred to as shId1 and shcontrol, respectively, were maintained in
1 μg/ml puromycin, 200 mg/ml G418, and 10% FBS.
Cell Viability/Cytotoxicity and Invasion Assays
Cell viability was quantified by 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide assay (Trevigen, Gaithersburg, MD).
Cells (1 × 103) were seeded per well in 96-well plates and allowed
to adhere overnight. Cells were treated with nicotine (1 μM) and/or
5 μM of gemcitabine (Gemzar) and cellular proliferation and viabil-
ity assayed after 48 hours using published protocols [16]. Boyden
chamber assays were conducted to measure invasion, as described
before [10,26].
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siRNA Transfections
Id1, Src, and α7 nAChR subunit siRNA oligonucleotides were
purchased from Santa Cruz Biotechnology (Sta Cruz, CA). Non-
target siRNA was used as the control. Pancreatic cancer cells were
transfected either with control (100 pmol), Id1 (100 pmol), Src
(100 pmol), or α7 nAChR subunit (50 pmol) siRNA using Oligo-
fetamine (Invitrogen, Grand Island, NY). Western blot analysis was used
to monitor the expression level of Id1, Src, and α7 nAChR subunit.
Reverse Transcription–Polymerase Chain Reaction and
Quantitative Real-time Polymerase Chain Reaction
RNAwas isolated using the RNeasyMini Kit (Qiagen, Valencia, CA)
and cDNA was prepared with AMV reverse transcriptase (Promega,
Madison, WI). Polymerase Chain Reactions (PCRs) were performed
using 1 μg of cDNA. Primers (Integrated DNATechnologies, Coralville,
IA) used for amplifying α7 nAChR subunit are previously described
[10,31]. PCR products were analyzed on a 1% agarose gel in TAE 1×
buffer using glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
expression as a loading control [10].
Id1 mRNA levels were analyzed by quantitative real-time PCR on a
Biorad iCycler. The primers used were Id1-forward primer, 5′-GAG
CTG AAC TCG GAA TCC GAA G-3′ and Id1-reverse primer, 5′ GAT
CGT CCG CAG GAA CGC ATG C3′. Data were normalized using
18S RNA as internal control and the fold change in the expression rel-
ative to nontargeting siRNA was determined.
Mouse Xenograft Experiments
Single-cell suspensions in Dulbecco’s PBS were used for implanta-
tion in 8-week-old female athymic nude mice (Charles River Labora-
tories, Wilmington, MA); viability of the cells used was greater than
90%, as determined by trypan blue exclusion. Orthotopic implanta-
tion of pancreatic tumor cells was performed as previously described
[16]. One week after implantation, mice were administered nicotine
(1 mg/kg, every Monday/Wednesday/Friday), gemcitabine (250 mg/kg,
Tuesday/Thursday), or PBS control through intraperitoneal injec-
tions. Tumor growth was monitored by IVIS200 imaging. Mice were
killed 4 weeks after implantation, and primary tumors, regional peri-
pancreatic (celiac and para-aortic) lymph nodes, and livers were exam-
ined for tumor cells by ex vivo imaging.
Patients
The study cohort included patients who underwent pancreatic
resections between 1986 and 2006 at the H. Lee Moffitt Cancer
Center and Research Institute. Patients were identified by searching
the surgical databases, the pathology information system, and the
Moffitt Cancer Registry. Data from the Moffitt Cancer Registry, the
patient’s medical record, and the Social Security Death Index were
reviewed to determine overall survival. The slides of the pancreatic
resections were reviewed by a pathologist (B.A.C.), and the histo-
pathologic features including grade and tumor type were established.
All data were collected under Institutional Review Board (IRB) approval.
Pancreatic Cancer TMAs
Pancreatic ductal adenocarcinoma resected at the Moffitt Cancer
Center from 1987 to 2006 was used to generate TMAs. Tissue speci-
mens were fixed and processed into paraffin blocks, and two separate
cores, 0.6 cm in diameter, were obtained for each area of carcinoma
and from the nonmalignant areas of the same patient. TMAs were
stained with hematoxylin and eosin (H&E) [16] and grade (I–IV)
was assigned to the each core using a standard grading system based
on tubular differentiation [CAP (College of American Pathologists)
protocols]. The first two TMAs consisted of 50 nonmalignant cores
and 50 paired carcinoma cores, and the third comprised 44 non-
malignant cores and 44 carcinoma cores.
Immunohistochemistry
Immunohistochemical (IHC) staining was performed using a
Ventana Discovery XT Automated System (Ventana, Tucson, AZ)
as per the manufacturer’s protocol [32]. Primary antibodies against
Id1 (BioCheck), phospho-Src416 (Millipore, Billerica, MA), and Src
(Epitomics, Burlingame, CA) were used for IHC.
Scoring of IHC. Both the intensity and percentage of cells expres-
sing Id1, pSrc, and Src were assessed using a previously established
and recognized semiquantitative scoring system for IHC staining
[33,34]. The intensity of staining was assessed as 0 (absent), 1+ (weak),
2+ (moderate), and 3+ (strong) for Id1 and as 0 (absent), 1+ (weak),
2+ (moderate), 3+ (strong), and 4+ (very strong) for pSrc and Src.
A visual histoscore was assigned to each core, which consisted the
sum of the products of the intensities times the percentage of posi-
tive cells per intensity.
Densitometric analysis of IHC. TMA slides were scanned using the
ScanScope XT (Aperio, Vista, CA) with a ×200/0.75 NA objective lens
at a rate of 3 minutes per slide via Basler trilinear array.
Regions for analysis were manually selected by the study patholo-
gist (B.A.C.).
Immunopositivity of each biomarker was quantitatively scored
using the TissueStudio v3.0 software platform from Definiens
(Munich, Germany). The staining intensity for very strong (4+),
strong (3+), moderate (2+), weak (1+), and negative (0) compart-
ments were threshold by the pathologist (B.A.C.) and locked to
ensure consistency throughout the study. For each case, the number
and percentage of each classified group of cells was exported for
statistical analysis.
Statistical Analyses
Statistical analysis for the experiments was performed using two-
tailed Student’s t test. Experiments were performed in triplicate and
values were considered significant when the P value was <.05. Cor-
relation of IHC expression with grade in human samples was per-
formed by comparing the grade within each core to the histoscore
for the antibody. To compare IHC expression to patient level vari-
ables, such as overall grade and survival, we calculated the mean value
for protein expression per patient. To compare grade within each
core, or overall grade, to IHC expression, Spearman rho statistic
was used, along with associated P values. To compare IHC expres-
sion to survival, we fit a Cox proportional hazards regression model.
We also split IHC expression into high and low expression using the
75% cut point to compare the high 25% to low 75% IHC expres-
sion of Id1. To compare the high and low expression groups, we fit
Kaplan-Meier survival curves and tested the difference using a log-
rank test. Overall grade was grouped into low (1/2) and high (3/4)
grades to fit Kaplan-Meier survival curves and tested the difference
using a log-rank test. To compare pathologist to algorithm expres-
sion, we considered the Spearman rho statistic, along with associated
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P value. All tests were considered two-sided unless otherwise speci-
fied, and the patient-related analysis was performed using SAS 9.3
and R 2.14.2.
Results
Nicotine Promotes Id1 Expression through a Src-dependent
Signaling Axis
Nicotine has been shown to promote the proliferation of cells,
invasion, and angiogenesis through nAChRs [20,35]. As described
in previous reports, the tumor promoting effects of nicotine have
been mediated primarily by ligand binding to the α7 nAChR subunit
[36]. To determine if nicotine could affect pancreatic adenocarcinoma
cells through this receptor, we examined the presence of α7 nAChR in
pancreatic cancer cell lines L3.6pl, L3.6plGemRes, PANC-1, andMia-Pa-
Ca-2. Semiquantitative reverse transcription–PCR showed the presence
of α7 nAChR subunitmRNA in all the four cell lines tested (Figure 1A).
This raises the possibility that these pancreatic cancer cell lines would
be able to respond to the tumor-promoting effects of nicotine.
We next determined the effect of nicotine on Src tyrosine activity,
which is known to promote proliferation as well as chemoresistance.
Stimulation of pancreatic cancer cells L3.6pl with nicotine demon-
strated an increase in Src phosphorylation (Figure 1B), as has been
reported before [13]. The phosphorylation levels were markedly higher
15 minutes after stimulation and persisted for at least 1 hour and no
appreciable change in the levels of total Src protein. Similar results were
noted in PANC-1 and L3.6plGemRes pancreatic cancer cells (Figure 1,
C and D), suggesting that exposure to nicotine can induce Src kinase
activation in multiple pancreatic cancer cell lines.
Because Id1 transcription factor is a downstream target of Src
signaling in NSCLC cells, experiments were conducted to assess
whether nicotine stimulation led to an induction of Id1 expression
in multiple pancreatic cancer cell lines. Western blot analysis of
lysates from nicotine-stimulated L3.6pl and L3.6plGemRes pancreatic
cancer cells showed an induction of Id1 protein 4 hours after nico-
tine stimulation, and the levels remained elevated at least for 24 hours
(Figure 2, A and B, respectively). These results were confirmed in
PANC-1 and MIA-PaCa-2 cells at 4 hours (Figure 2C ). To examine
whether the induction occurred at the transcriptional level, we con-
ducted real-time PCR experiments on quiescent or nicotine-stimulated
cells. It was found that stimulation with 1 μM nicotine leads to a two-
fold to four-fold induction of Id1 expression in a panel of cell lines,
suggesting that nicotine induced Id1 levels at the level of transcription
(Figure 2D).
Attempts were then made to determine if the signaling events lead-
ing to an increase in Id1 expression are dependent on the α7 nAChR
and Src in L3.6pl pancreatic cancer cells. Toward this purpose,
L3.6pl cells were transfected with an siRNA to α7 nAChR subunit
or a nontargeting control siRNA. Cells were rendered quiescent by
serum starvation and stimulated with 1 μM nicotine for 6 hours.
Western blot analysis showed that transfection with the α7 nAChR
siRNA led to a marked reduction in the levels of this receptor; there
was no reduction in the levels of Src (Figure 3A). Nicotine stimula-
tion of control siRNA–transfected cells led to a modest increase in
the levels of Src and a significant increase in the levels of Id1 protein
as seen by Western blot analysis. There was no increase in cells trans-
fected with an siRNA to α7 nAChR (Figure 3A), suggesting that this
subunit is necessary for the nicotine-mediated induction of Id1.
Similarly, depletion of Src by siRNA prevented nicotine-mediated
induction of Id1 (Figure 3B). The requirement for Src for the nicotine-
mediated induction of Id1 was further verified using dasatinib, a Src
kinase inhibitor. L3.6pl cells were rendered quiescent by serum starva-
tion and stimulated with serum or 1 μM nicotine in the presence or
Figure 1. Nicotine induces Src phosphorylation in pancreatic adenocarcinoma cells. (A) Expression of α7 subunit of nAChR as seen by
reverse transcription–PCR in a variety of pancreatic cancer cell lines. (B) Quiescent L3.6pl metastatic pancreatic cancer cells stimulated
with nicotine induce Src phosphorylation within 1 hour. (C and D) Nicotine induces Src phosphorylation in PANC-1 and acquired
gemcitabine-resistant L3.6plGemRes pancreatic cancer cells with a maximal phosphorylation event at 1 hour with return to baseline within
4 hours.
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Figure 2. Nicotine induces Id1 protein expression in pancreatic adenocarcinoma cells. (A and B) L3.6pl and acquired gemcitabine-
resistant L3.6plGemRes demonstrate significant increases in Id1 expression when quiescent cells are exposed to 1 μM nicotine. (C) Sim-
ilarly, nicotine induces Id1 expression in PANC-1 and Mia-PaCa-2 pancreatic cancer cells. (D) Nicotine stimulation leads to increased Id1
mRNA expression levels in a diverse sample of pancreatic cancer cells lines, suggesting that the induction is at the transcriptional level.
Figure 3. Nicotine induces Id1 expression in a Src-dependent manner and regulates proliferation and invasion of pancreatic adeno-
carcinoma cells. (A) Silencing of α7 nAChR inhibits nicotine-induced Src and Id1 expression L3.6pl pancreatic cancer cells. (B) Silencing of Src
expression inhibits nicotine induction of Id1 expression in L3.6pl pancreatic cancer cells. (C) Pharmacologic inhibition of Src phosphorylation with
dasatinib inhibits constitutive and nicotine-induced levels of Id1 expression in L3.6pl pancreatic cancer cells. (D) shRNA to Id1 expression demon-
strates significantly less Id1 when compared to controls (inset). Nicotine promotes cell viability and silencing of Id1 significantly diminishes this
effect. (E and F) Nicotine promotes invasion in L3.6pl and PANC-1 pancreatic cancer cells and silencing of Id1 significantly diminishes this effect
as demonstrated by cells per high-power field (HPF) and hematoxylin staining of both pancreatic cancer cells on membrane (inset).
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absence of 500 nM dasatinib. It was found that inhibiting Src kinase
completely eliminated Src phosphorylation as well as induction of Id1
by both nicotine as well as serum (Figure 3C ). These results show that
α7 nAChR and Src are involved in the induction of Id1 by nicotine in
pancreatic cancer cells and that Id1 is a mediator of Src function in
these cells.
Depletion of Id1 Inhibits Nicotine-induced Proliferation and
Invasion of Pancreatic Cancer Cells
Our earlier studies had shown that nicotine could induce the pro-
liferation and invasion of lung cancer cells and Id1 played a role in
this process. Experiments were conducted to examine whether nico-
tine induced similar events in pancreatic cancer cells and whether Id1
was necessary for this. Toward this purpose, L3.6pl pancreatic cancer
cells stably transfected with a control, a nontargeting shRNA, or an
shRNA to Id1 were rendered quiescent by serum starvation and
subsequently stimulated with 1 μM nicotine. As expected, cells trans-
fected with an shRNA to Id1 had significantly less Id1 (Figure 2D,
inset); stimulation with nicotine increased the number of control
shRNA–transfected cells but not shId1-transfected cells, as seen by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay
(P < .001; Figure 3D). Similarly, Boyden chamber assays were con-
ducted to assess the role of Id1 in nicotine-mediated invasion of
L3.6pl and PANC-1 pancreatic cancer cells. As shown in Figure 3,
E and F , nicotine-stimulated control cells invaded through the
matrix effectively, but invasion was greatly impaired in cells depleted
of Id1 (P < .001). This suggests a definite role for Id1 in mediating
nicotine-induced proliferation and invasion of pancreatic cancer cells.
Nicotine Promotes Chemoresistance in Pancreatic Cancer Cells
One clinical challenge in the management of pancreatic cancer is
the resistance to chemotherapeutic treatment strategies [5]. There-
fore, we identified pancreatic cancer cells with sensitivities to gemci-
tabine, the first-line chemotherapeutic agent for patients with
pancreatic cancer, to determine the role of nicotine and Id1 in che-
moresistance. To study acquired chemoresistance, we established
gemcitabine resistance in the L3.6pl gemcitabine-sensitive cell line,
L3.6plGemRes, as described previously [37]. A panel of pancreatic can-
cer cells was exposed to 5 μM gemcitabine, and Western blot anal-
yses were conducted for cleavage of PARP, indicative of apoptosis.
It was found that gemcitabine induced apoptosis in L3.6pl and
Mia-PaCa-2 cells (Figure 4A) but not in PANC-1 cells, which was
innately resistant neither to gemcitabine nor in the L3.6plGemRes
cells, which had acquired resistance to gemcitabine. To assess
whether nicotine affected the sensitivity of the cells to gemcita-
bine, we treated L3.6pl and L3.6plGemRes cells with gemcitabine in
the presence or absence of nicotine. It was found that gemcitabine
reduced the viability of L3.6pl cells by about 80% but not
L3.6plGemRes cells; nicotine increased the viability of both the cell
lines by about 60% (Figure 4B). Interestingly, gemcitabine treatment
in the presence of nicotine completely reversed the gemcitabine
sensitivity of L3.6pl cells. This suggests that nicotine has protective
effects on pancreatic cancer cells as well and might reduce chemo-
sensitivity in patients.
The effects of nicotine on gemcitabine resistance were also deter-
mined in vivo. Luciferase expressing L3.6pl gemcitabine–sensitive
metastatic variant cells were orthotopically implanted into the pan-
creas of SCID mice and randomized to control PBS, nicotine, gem-
citabine, or nicotine + gemcitabine. Nicotine was administered
3 days per week at 1 mg/kg and gemcitabine was administered
250 mg/kg 2 days a week. As shown in Figure 4C , administration
of nicotine enhanced the growth of tumors in vivo, whereas admin-
istration of nicotine significantly reduced the growth of tumors (P <
.001), as determined by luciferase expression (photons per second).
At the same time, administration of nicotine significantly inhibited
the chemotherapeutic effects of gemcitabine, and tumors were com-
parable in size to control, untreated mice. Measurement of tumor
volumes at the termination of the experiment after 4 weeks con-
firmed these results (Figure 4D). It was also found that nicotine pro-
moted pancreatic tumor liver metastases regardless of gemcitabine
exposure (Figure 4E ) as quantified by luciferase expression in liver
ex vivo. The luciferase expression in the liver, which is suggestive
of pancreatic cancer liver metastases, was confirmed by H&E
(Figure 4F ) for each group. Thus, while gemcitabine had a therapeu-
tic effect on L3.6pl cells in mice, exposure to nicotine abrogated this
effect and established a chemoresistant phenotype.
Depletion of Id1 Expression Reverses Acquired and Innate
Gemcitabine Chemoresistance and Inhibits Nicotine-induced
Primary Tumor Growth and Metastases
It has been demonstrated that Src activity regulates gemcitabine
chemoresistance in preclinical pancreatic cancer models [17,18],
but the downstream modulators of Src-mediated chemoresistance
are not known. Because we had observed that Id1 is a downstream
target of Src, we examined whether Id1 contributes to chemoresis-
tance. Toward this purpose, L3.6plGemRes cells as well as PANC-1
cells were transiently transfected with siRNA to Src as well as Id1
or a nontargeting control siRNA. Cells were treated with 5 μM gem-
citabine and apoptosis was assessed by Western blot analysis for
PARP cleavage. As shown in Figure 5, A and B, depletion of Id1
expression in acquired and innate gemcitabine-resistant L3.6plGemRes
and PANC-1 cells resulted in PARP cleavage and sensitization to
gemcitabine. This suggests that Id1 is a potential mediator of che-
moresistance induced by Src.
To determine if the effects of nicotine on pancreatic cancer cells
observed could be via Id1, in vivo experiments were conducted. To-
ward this purpose, metastatic L3.6pl cells stably expressing a lucifer-
ase gene were transfected with a control shRNA or an shRNA to Id1
and orthotopically implanted into the pancreas of SCID mice. Nic-
otine (1 mg/kg) was administered by intraperitoneal injection three
times a week and tumor growth was assessed by IVIS200 imaging.
Correlating with our in vitro data, nicotine promoted primary tumor
growth over a period of 4 weeks as determined by luciferase expres-
sion as photons per second (Figure 5C ). While the growth of control
shRNA–transfected cells was promoted by nicotine, there was no
stimulation in the growth of cells transfected with Id1 shRNA; in-
deed, these cells hardly formed any tumors in mice. In agreement
with the luciferase expression data (Figure 5D, inset), tumors stimu-
lated with nicotine had a larger volume as measured at the termina-
tion of the experiment and the largest tumors were in control cells
that were stimulated with nicotine (Figure 5D). IHC analyses of the
primary tumors demonstrated an induction of pSrc in tumors ex-
posed to nicotine, compared to tumors from control mice. Although
nicotine was able to increase Id1 expression in control tumors, this
effect was not observed in tumors derived from pancreatic cancer
cells with stable Id1 depletion (Figure 5E ), despite the fact that phos-
phorylation of Src was increased in these tumor cells.
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Figure 4. Nicotine induces a chemoresistant phenotype in pancreatic cancer cells and tumors. (A) Gemcitabine induces PARP cleavage in
L3.6pl and Mia-PaCa-2 cells and not in acquired and innate resistant cells L3.6plGemRes and PANC-1, respectively (left panel). (B) Nicotine in-
duces cell viability/proliferation in both sensitive L3.6pl and acquired chemoresistant L3.6plGemRes cells and nicotine induces a chemoresistant
phenotype in the chemosensitive L3.6pl pancreatic cancer cell line. (C) Tumor growthmonitored by luciferase activity (photons per second) in
L3.6pl gemcitabine–chemosensitive cells demonstrates augmented growth in mice treated with nicotine, containment of tumor growth in
mice treated with gemcitabine, and continued tumor growth in mice treated with nicotine and gemcitabine comparable to control with in vivo
luciferase imaging ofmice at termination of experiment demonstrating these effects (inlet). (D) Graph demonstrating the corresponding tumor
volume (mm3) fromeach animal group. (E) Ex vivo imagingof livers, fromeach animal group, demonstrates significantly higher livermetastasis
inmice treatedwith nicotinecompared to control, no livermetastasis inmice treatedwithgemcitabine, andoverall increasedsignal from liver in
mice treatedwith nicotine and gemcitabinewhen compared to all groups as seen by quantification of luciferase activity (photons per second).
(F) H&E staining of liver metastases (T) confirming metastatic deposits of pancreatic tumor adjacent to normal liver parenchyma (N).
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Figure 5. Depletion of Id1 abrogates chemoresistant phenotype and tumorigenic properties of pancreatic cancer cells. (A) Depletion of
Src and Id1 using siRNA induces PARP cleavage in L3.6plGemRes-acquired–resistant pancreatic cancer cells exposed to gemcitabine
therapy. (B) Depletion of Id1 expression in innate chemoresistant PANC-1 cells induces PARP cleavage and resensitizes cells to the
cytotoxic effects of gemcitabine. (C) Tumor growth monitored by luciferase activity (photons per second) over approximately 4 weeks
demonstrates increased tumor burden in mice treated with nicotine, whereas Id1 depletion resulted in inhibition of tumor growth
regardless of nicotine exposure. (D) Graph showing the corresponding tumor volume (mm3) from each animal group corresponding
to in vivo luciferase imaging of mice at termination of experiment (inset) demonstrating the promoting effects of nicotine and the sup-
pressive effects of Id1 silencing on primary tumor growth. (E) Nicotine-induced pSrc and Id1 expression levels in primary tumors in vivo
while having no effect on Id1 expression in tumors originating from cells with stably transfected shRNA silencing of Id1. (F) Ex vivo
quantification of luciferase activity (photons per second) from livers demonstrates significantly higher liver metastasis in mice treated
with nicotine while demonstrating no liver metastasis in mice with tumors derived from Id1-depleted cells. (G) H&E staining of livers (N)
with metastatic pancreatic tumor demonstrates increased expression of Id1 in metastatic deposits (M).
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L3.6pl cells are highly metastatic, which resemble human pan-
creatic cancer; hence, livers of mice were examined for metastatic foci
at the termination of the experiment. Liver metastases were detected
by luciferase expression ex vivo and confirmed by H&E staining in
mice implanted with cells transfected with control shRNA, both
vehicle and nicotine-stimulated animals. It was found that nicotine
stimulation had promoted the metastasis of L3.6pl cells to the liver;
at the same time, stable knockdown of Id1 expression significantly
decreased this metastatic potential regardless of nicotine exposure
(P < .001; Figure 5F ). IHC analyses of liver metastases confirmed
disease and also demonstrated an increased Id1 expression level
(Figure 5G ). These results suggest that nicotine can induce a more
aggressive phenotype potentially through by a Src-Id1 signaling axis
in vivo and depletion of Id1 expression can inhibit these effects.
Id1 Expression Correlates with Src Activation, Poor Tumor
Differentiation, and Reduced Overall Survival in
Human Pancreatic Cancer Patients
Because Id1 and Src appear to be involved in the proliferation as
well as survival of pancreatic adenocarcinoma cells, experiments were
conducted to assess whether there is a correlation between the levels
of these proteins and tumor grades in surgically resected patients. As
a first step, a total of 130 resected specimens were confirmed by H&E
for malignancy and subsequently stained for Id1, pSrc, and total Src
(Figure 6). Assessment of pathologic grade of the resected specimen
showed the following distribution in these patients: 30 grade I car-
cinomas, 74 grade II, 25 grade III (including 1 squamous cell carci-
noma), and 1 grade IV. The grades were combined into two groups,
low grade (grade I + grade II) and high grade (grade III + grade IV),
for the purpose of statistical analysis. Ninety-two patients had eval-
uable expression for Id1, of a total of 140 cores analyzed (8 grade I,
83 grade II, 48 grade III, and 1 grade IV). Eighty-seven patients had
evaluable pSrc expression, with 136 cores containing cancer analyzed
(19 grade I, 85 grade II, 19 grade III, and 3 grade IV). Ninety-seven
patients had evaluable Src expression for Src with 166 cores analyzed.
IHC staining of pancreatic tumors of worsening differentiation
demonstrated increased expression of Id1 and pSrc expression levels
(Figure 6). Further quantitative analyses demonstrated a statistically
significant (P = .009) correlation between Id1 and phospho-Src levels.
Levels of pSrc and Id1 expression significantly correlated indepen-
dently with tumor grade/differentiation (P = .0005, Figure 7A and
P = .0006, Figure 7B, respectively). Analysis of overall survival and
Figure 6. Id1 expression in resected human pancreatic adenocarcinoma. TMAs constructed from resected pancreatic ductal adenocar-
cinoma were stained for Id1, pSrc (activated form), and total Src using standard IHC techniques. A statistically significant correlation was
observed between Id1 and tumor grade/differentiation and pSrc expression levels. No significant correlation was seen between total Src
and Id1 expression.
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Figure 7.Worsening tumor grade correlates with increased pSrc and Id1 expression levels and increased Id1 expression correlates with
poor overall survival in pancreatic cancer patients. (A) Increased tumor grade level demonstrates a clear correlation with higher pSrc
expression levels (score) with a Spearman correlation estimate of 0.31 (P < .001). (B) Increased tumor grade level is associated with
increased Id1 expression (score) with a Spearman correlation estimate of 0.29 (P < .001). (C) Patients with high histologic grade have
significantly worse survival than patients with low histologic grade (P = .0235). (D) Dichotomizing Id1 scores into low and high scores
using the 75% score demonstrates significant correlation with overall patient survival, with high Id1 expression levels resulting in a
worse overall survival (P = .0388). (E) Increased tumor grade level demonstrates a significant correlation with increased Id1 expression
(algorithmic densitometric analyses) with Spearman correlation estimate of 0.24 (P = .0042). (F) Dichotomizing Id1 scores (determined
by quantitative algorithm) into low and high scores with 75% score demonstrates a significant correlation with overall patient survival
with high Id1 expression levels resulting in a worse overall survival (P = .0519).
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tumor grade was also significant (P = .0186, Figure 7C ); the cor-
relation between patient overall survival and Id1 expression as a con-
tinuous variable was statistically significant (P = .0225). When
dichotomizing Id1 expression levels into high and low expression
using the 75% cut point to fit Kaplan-Meier survival curves, a signif-
icant difference was also observed for overall survival with patients
with higher Id1 expression levels having a worse overall survival (P =
.0388, Figure 7D). Thus, Id1 and pSrc expression not only correlated
with each individual expression level, but they also independently cor-
related with decreased tumor differentiation. Most importantly, as Id1
expression levels increased in resected pancreatic tumors, patients had a
decrease in overall survival.
Supporting our results above, quantitative densitometric analyses
were performed on the IHC correlations of Id1, pSrc, and Src. To this
effect, TMAs were scanned and analyzed as described in Materials and
Methods section. Pathologist semiquantitative histoscore and algo-
rithmic values produced from our densitometric analyses were com-
pared using the Spearman correlation coefficient. There was a strong
correlation between pSrc and Id1 pathologist when compared to algo-
rithmic values, with a correlation coefficient of 0.71 (P < .001) and
0.65 (P < .001), respectively, and a moderate correlation between
pathologist and algorithmic values of Src, with a correlation coefficient
of 0.31 (P < .001). Comparison of algorithmic Id1 to pSrc expression
levels also demonstrated a significant correlation coefficient of 0.72 (P <
.0001). Supporting our semiquantitative analyses, algorithmic Id1
expression levels significantly correlated independently with tumor
grade/differentiation (P = .0186). When comparing overall patient
survival with Id1 algorithmic values, the significance level increases only
slightly, to P = .0519, but comparable to semiquantitative pathologic
values. These results indicate that the pathologist semiquantitative
histoscore method is an effective method for assessing protein expres-
sion in the case of the antibodies used in this study.
Altogether, these results suggest a Src-Id1 signaling axis that might
contribute to pancreatic tumor progression, decreased tumor differ-
entiation, and worse clinical outcomes.
Discussion
Although humans express four types of Id1 protein, increasing evi-
dence supports the function of the HLH protein Id1 as an oncogene
in more than 15 types of epithelial cancers [22,38–40] through in-
activation of p16INK4a/RB and p53 tumor suppressors, two early
hallmark mutations in pancreatic ductal adenocarcinoma [21]. Id1
facilitates the growth and metastases of NSCLC cells in response
to nicotine activation of the α7 nAChR [20]. Previous studies dem-
onstrate that nicotine can also inhibit apoptosis by up-regulation of
XIAP and survivin through up-regulation of a Src-dependent PI3K/
Akt pathway [9] and these effects might be through an autocrine
catecholamine loop that is activated by nAChRs [13], or directly
through α7 receptors as seen in NSCLC cells. The tumor-promoting
effects of nicotine and cigarette smoke have also been recently re-
ported in pancreatic cancer through MUC4-mediated signaling
[14]. Although Id1 has been implicated as a tumor promoter in a
variety of systems, the effects of tobacco components such as nicotine
on Id1 and how it effects pancreatic tumor progression and chemo-
resistance are poorly understood. Previous data have reported that
inactivation of Id1 promotes chemosensitivity in prostate and naso-
pharyngeal cancer cells, through activation of the c-Jun N-terminal
kinase and Raf/MAP kinase kinases (MEK) pathways, respectively
[25,41]. In our studies, we demonstrated that nicotine induction of
Id1 expression results in enhanced malignant properties and chemo-
resistance in pancreatic cancer.
Pancreatic cancer remains an insistent disease partly due to innate
or the development of acquired resistance to chemotherapy [5].
Patients with intrinsic drug resistance suggest that therapy will be in-
effective from the initiation of therapy, whereas those with acquired
drug resistance develop this phenotype after exposure to therapy.
Interestingly, cancer cells that develop acquired resistance initially
demonstrate some efficacy to treatment, but continued treatment
can lead to progression of disease. The mechanisms into acquired
chemoresistance are the acquisition of ATP-binding cassette trans-
porters, which clear chemotherapeutic drugs from cancer cells, un-
responsive drug-induced apoptosis, and initiation drug detoxification
mechanisms [42], whereas the tumor microenvironment has been
implicated in innate chemoresistance [43]. Signaling proteins such as
Akt, nuclear factor-kappaB (NF-κB), and MAP/ERK kinase, as well
as secreted proteins such as vascular endothelial growth factor, have
been identified as having important roles in drug resistance in pancre-
atic cancer [44–46], and previous reports suggest that Src kinase is an
upstream signaling such proteins mentioned above [47–49]. Therefore, it
is not surprising that Src tyrosine kinase overactivity represents a chemo-
resistant mechanism in pancreatic cancer preclinical models. Specif-
ically, inhibition of Src activity or expression augmented gemcitabine-
induced caspase-mediated apoptosis, suppressed RRM2 expression,
and decreased activity of the RRM2-regulating transcription factor
E2F1 [17,18]. Smoking is a principal risk factor for pancreatic cancer
with nicotine as the additive component and nicotine has been demon-
strated to promote tumor growth and angiogenesis and protect cancer
cells from apoptosis in lung cancer models in a Src-dependent manner
[9,20,50]. In our studies, we present a novel Src-dependent mecha-
nism for gemcitabine resistance regulated by the tumor-promoting effects
of nicotine.
In the present era, pancreatic cancer remains a devastating disease
with adjuvant therapies providing modest clinical results. Identifica-
tion of key molecular targets that enhance chemoresistance to these
therapies is critical. We believe that the malignant and chemoresis-
tant properties of pancreatic cancer might be enhanced by tobacco
exposure act through a Src-dependent Id1 signaling axis. Our work
provides support for population-based studies that show patients
who continue to smoke after cancer diagnosis have a poor prognosis
compared to nonsmokers. Our studies also suggest that the clinical
assessment of Id1 expression might be a good biomarker of prognosis
and support further investigations toward targeting this protein for
potential pancreatic cancer therapy.
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